Immunotherapy and Immune-Related Adverse Events in Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: 28 February 2026 | Viewed by 36
Special Issue Editor
2. Department of Gastroenterology, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia
3. Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia
Interests: immunotherapy; transplantation; hepatology; microbiota; digestive oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunotherapy has significantly improved survival rates for some cancers, particularly in patients with advanced or metastatic disease. For example, in melanoma, immunotherapy, specifically PD-1 inhibitors, has increased the 5-year survival rate to approximately 50%, according to the Cancer Research Institute. In some cases, combination immunotherapy has shown even more impressive results, with over half of advanced melanoma patients surviving ten years or more. Despite the clinical benefits of the immune checkpoint blockade therapy, its use is associated with a spectrum of side effects, related to the mechanism of action, which is quite different from other systemic therapies such as cytotoxic chemotherapy (CTX). The side effects may involve any organ or system of the body; however, GI, dermatologic, hepatic, endocrine, and pulmonary toxicities predominate, and there should be a high level of suspicion that any changes are treatment-related. The incidence and onset of immune-related adverse effects (irAEs) vary based on the class and dose of ICPi administered, the type of cancer, and factors related to the patients. These events occur because immunotherapy, which boosts the immune system to fight cancer, can sometimes cause the immune system to attack healthy tissues. IrAEs can range from mild and easily managed to severe and life-threatening. With the increasing use of immunotherapy in cancer treatment regimens, it is imperative that clinicians be knowledgeable about the symptoms associated with these agents, how best to monitor them, and their recommended management. The aim of this thematic Special Issue is to cover the diagnosis and treatment of immune-mediated adverse events.
Prof. Dr. Ivana Mikolašević
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- cancer
- PD-1 inhibitors
- immune-related adverse effects
- management
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
